Baby KJ Thriving After Custom CRISPR Therapy World First

Baby KJ faced a terrifying future when he was born unable to convert ammonia into urea, putting his brain and liver at immediate risk of fatal damage.

The Pennsylvania newborn had severe CPS1 deficiency, a rare genetic disorder that made his tiny body unable to process protein without dangerous ammonia buildup. Doctors placed him on restrictive medications and a protein-free diet just to keep him alive, but at just months old, he was too small for a life-saving liver transplant.

His parents, Nicole and Kyle Muldoon, faced an impossible choice. Then two doctors at Children's Hospital of Philadelphia offered hope: a custom-made CRISPR gene therapy designed specifically for their son's unique genetic mutation.

Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru had spent years developing techniques to use CRISPR for ultra-rare diseases. Most approved gene therapies target conditions affecting tens of thousands of patients because the technology is complex and expensive. KJ's disorder affects only a handful of children worldwide.

Within six months, the team designed and manufactured a base editing therapy delivered through tiny lipid nanoparticles directly to KJ's liver. The treatment targeted his specific CPS1 variant to correct the faulty enzyme causing his condition.

KJ received his first infusion in late February 2025, followed by doses in March and April. The results stunned even his medical team.

The Ripple Effect

KJ suffered zero side effects from the experimental treatment. He's now off all medications and can eat some protein, something his parents never thought possible. While he'll need monitoring for life, he's thriving like any other baby his age.

The breakthrough proves that personalized CRISPR therapy can be developed quickly enough to save individual patients with ultra-rare genetic disorders. The methodology published in the New England Journal of Medicine creates a roadmap for other families facing similar diagnoses.

"We thought it was our responsibility to help our child," Nicole told CHOP. "We put our trust in them in the hopes that it could help not just KJ but other families in our position."

Years of collaboration between researchers and clinicians made KJ's treatment possible. The doctors belong to the NIH-funded Somatic Cell Genome Editing Consortium, which has worked to make precision medicine accessible beyond the most common genetic conditions.

The success opens doors for millions of children and adults worldwide suffering from extremely rare genetic disorders previously considered untreatable. What once seemed like science fiction is now giving families real hope and healthy babies.

KJ's story proves that even when a condition affects just one child, medicine can rise to meet the challenge.